荆州市捷顺机械制造股份有限公司

  • HOME

  • API

    • Fospropofol Disodium

    • Dexmedetomidine Hydrochloride

    • Flurbiprofen Axetil

    • Rocuronium Bromide

    • Sugammadex Sodium

    • Fosaprepitant Dimeglumine

    • Granisetron

    • Gadoxetate Disodium

  • VETERINARY API

  • INTERMEDIATE

    • (S)-N1-(2-aminoethyl)-3-(4-ethoxyphenyl)propane-1,2-diamine.3HCl

    • 4-bromo-3-(hydroxymethyl)phenol

    • (6bR,10aS)-Ethyl 3-methyl-2-oxo-2,3,6b,7,10,10a-hexah ydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3- de]quinoxaline-8(9H)-carboxylate

    • 2-bromo-5,6-dichloro-1H-benzo[d]imid azole

  • IMPURITY

  • ADVANTAGES

    • APPLICATION

  • ABOUT US

    • Company Profile

    • Development

    • Culture

    • Honor

  • NEWS

    • Company News

    • Industry News

  • CONTACT

HUMANWELL HEALTHCARE
HUMANWELL HEALTHCARE
  • Home page

disodium

Keywords:

Products News

Products

N-[4-bromo-2-(pyridine-2-carbonyl)phenyl]-2-chloroacetamide

(3S)-(7-BroMo-2-0xo-5-pyridin-2-y1-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionic acid Methyl ester

(1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine

(1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-ol

Ethyl (βR)-β-amino-2-bromo-6-(difluoromethoxy)benzenepropanoate

Osimertinib Mesylate

Baricitinib

Flunixin Meglumine

Atipamezole hydrochloride

Alfaxalone

News

Pioneering Achievement! Yichang Tianrui's Osimertinib Mesylate Secures Breakthrough Status, Leading the Future of High-End Pharmaceutical APIs

Exhibition Summary Report: Yichang Tianrui Biopharm Co., Ltd successful attented CPHI Frankurt 2025

Yichang Renfu has been successfully included in the Hubei Province 2025 5G Factory List.

Yichang Tianrui Biopharm Showcases Specialty API and CDMO Expertise at Jinan Pharma Partnering Forum

Strengthening the Safety Lifeline, Forging "Robust" Emergency Response Capabilities—Tianrui Pharmaceutical's Labor Competition Concludes Successfully

Yichang Renfu Pharmaceutical's Flurbiprofen Axetil Injection Receives Marketing Approval

API

Osimertinib Mesylate

Baricitinib

Maribavir

Letermovir

Samidorphan L-malate

Lumateperone Tosylate

Granisetron

Naltrexone

Gadoxetate Disodium

Landiolol hydrochloride

Enzalutamide

Rocuronium Bromide

Crisaborole

Sugammadex Sodium

Fosaprepitant Dimeglumine

Flurbiprofen Axetil

Regadenoson

INTERMEDIATES

N-[4-bromo-2-(pyridine-2-carbonyl)phenyl]-2-chloroacetamide

(3S)-(7-BroMo-2-0xo-5-pyridin-2-y1-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionic acid Methyl ester

(1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine

(1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-ol

Ethyl (βR)-β-amino-2-bromo-6-(difluoromethoxy)benzenepropanoate

2-(2-amino-5-bromobenzoyl)pyridine

ABOUT US

Company Profile

Development

Culture

Honor

CONTACT

Add:66 Tianjiahe Avenue, Baiyang Town, Baiyang,Industrial Park, High-tech Zone,Yichang City, Hubei Province, China. 
Tel:+86-717-4065884     +86-717-4065888

E-mail:yctr@renfu.com.cn

Copyright © 2024 YICHANG TIANRUI BIOPHARM CO., LTD All Rights Reserved.

POWERED BY  300.cn

E-mail:yctr@renfu.com.cn

WhatsApp:13714525239

Tel:+86-(0)717-4065884